Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GreenLight Biosciences Holdings GRNA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
38/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.00
+3572.8%

GreenLight Biosciences Holdings (GRNA) is a Biotechnology company in the Healthcare sector, currently trading at $0.30. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 2 out of 7 criteria passed.

Analyst consensus target is GRNA = $11 (+3572.8% upside).

Financials: revenue is $6M, -84%/yr average growth. Net income is $167M (loss), growing at -81.5%/yr. Net profit margin is -2616.8% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $80M against $48M equity (Debt-to-Equity (D/E) ratio 1.67, leveraged). Current ratio is 2.01 (strong liquidity). Debt-to-assets is 54.2%. Total assets: $149M.

Analyst outlook: 1 / 2 analysts rate GRNA as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 46/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$11.00
▲ 3572.79% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for GreenLight Biosciences Holdings, the average price target is $11.00, with a high forecast of $18.00, and a low forecast of $4.00.
Highest Price Target
$18.00
Average Price Target
$11.00
Lowest Price Target
$4.00

GRNA SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRNA

✓
VALUE Pass
100/100
GRNA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $11, implying +3572.8% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GRNA: -84%/yr revenue is, -81.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet GRNA: Debt-to-Equity (D/E) ratio 1.67 (leveraged), Current ratio is 2.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
GRNA: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 1 / 2 analysts rate GRNA as buy (50%). Analyst consensus target is $11 (+3572.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
GRNA: Net profit margin is -2616.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.177-5.9
Volume143.17K
Avg Volume (30D)684.8K
Market Cap$45.43M
Beta (1Y)1.44
Share Statistics
EPS (TTM)-1.27
Shares Outstanding$131.98M
IPO Date2022-02-03
Employees280
CEOAndrey Juan Zarur
Financial Highlights & Ratios
Revenue (TTM)$6.38M
Gross Profit$6.38M
EBITDA$-153.99M
Net Income$-167.06M
Operating Income$-163.92M
Total Cash$68.1M
Total Debt$80.48M
Net Debt$12.39M
Total Assets$148.6M
Price / Earnings (P/E)-0.2
Price / Sales (P/S)7.12
Analyst Forecast
1Y Price Target$11.00
Target High$18.00
Target Low$4.00
Upside+3,572.8%
Rating ConsensusBuy
Analysts Covering2
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS39536G1058

Price Chart

Track all markets on TradingView
GRNA
GreenLight Biosciences Holdings ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.18 52WK RANGE 5.90

People Also View

FHTX
FHTX
Foghorn Therapeutics Inc.
$4.87
+0.41%
 NTRB
NTRB
Nutriband Inc.
$4.08
+0.49%
 RNXT
RNXT
RenovoRx, Inc.
$1.02
-0.97%
 LGVN
LGVN
Longeveron Inc.
$1.12
-0.89%
 SNTI
SNTI
Senti Biosciences, Inc.
$0.94
+0.73%
 LEXX
LEXX
Lexaria Bioscience Corp.
$1.03
+0.98%
 CVKD
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$4.81
+0.42%
 ZIVO
ZIVO
ZIVO Bioscience, Inc.
$2.23
+5.19%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message